Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Clinical Pharmacology Study of KC-8025 in Healthy Japanese and Caucasian Adults
jRCT2071230101Phase 1Completed
- Sponsor
- Kaken Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of seladelpar, sponsored by Kaken Pharmaceutical Co., Ltd. Primary endpoints: Pharmacokinetics of KC-8025 and Safety and tolerability of KC-8025. Started Dec 2023; status: completed.
02
Drugs
seladelpar
Beyond the preview
Go deeper on jRCT2071230101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230101.